Amy Diane Dobberfuhl, MD
Urology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Offices
- 3
Offices
3 locations · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Dobberfuhl’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A133671 · Current
Licensed to practise in California · since 2014 · expires 2026-12-31 · University of North Carolina at Chapel Hill.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$59,318
Medicare paid this office $59,318 for 277 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 58 | $10,714 | $160 |
| Exam with injections of chemical for destruction of bladder using an endoscope | 48 | $9,072 | $131 |
| Return visit (30+ min) | 35 | $3,885 | $111 |
| Long return visit (40+ min) | 32 | $3,862 | $121 |
| Return visit (30+ min) | 41 | $3,540 | $82 |
See all 16 services
| Long return visit (40+ min) | 58 | $10,714 | $160 |
| Exam with injections of chemical for destruction of bladder using an endoscope | 48 | $9,072 | $131 |
| Return visit (30+ min) | 35 | $3,885 | $111 |
| Long return visit (40+ min) | 32 | $3,862 | $121 |
| Return visit (30+ min) | 41 | $3,540 | $82 |
| Dilation of bladder using an endoscope under general or spinal anesthesia | 13 | $2,677 | $178 |
| New patient visit (45+ min) | 17 | $1,849 | $109 |
| New patient visit (60+ min) | 12 | $1,790 | $149 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 19 | $1,755 | $92 |
| Diagnostic exam of bladder and urethra using an endoscope | 21 | $1,488 | $71 |
| Short return visit (20+ min) | 12 | $655 | $55 |
| Insertion of device into abdomen with pressure and urine flow rate study | 19 | $555 | $29 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 19 | $259 | $14 |
| Injection procedure for imaging of bladder during voiding | 11 | $208 | $19 |
| Review by radiologist of urinary bladder and urethra images with contrast and after passing urine | 16 | $183 | $11 |
| Electronic assessment of bladder emptying | 19 | $62 | $3 |
Procedures Medicare counted
| Prostate resection | 1-10 | None |
Who their Medicare patients are
277 Original Medicare patients in 2024. Average age 74 · Under 65 12% · 85 and older 14% · Women 59% · Also on Medicaid 25% · Health risk score 1.68. Above the middle of the specialty; the typical urology clinician is at 1.36.
Conditions among them: High blood pressure 71% · Diabetes 31% · Coronary heart disease 27% · Chronic kidney disease 27% · Depression 24% · Cancer 18% · Heart failure 16% · Atrial fibrillation 16% · COPD 13% · Stroke 10% · Dementia 8%.
The office billed $867,826, Medicare allowed $77,839 and paid $59,318; for 543 services of 55 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 277 | 543 | 74 | 1.68 | $867,826 | $59,318 |
| 2023 | 247 | 520 | 73 | 1.61 | $706,939 | $50,899 |
| 2022 | 199 | 456 | 72 | 1.49 | $627,989 | $39,925 |
| 2021 | 172 | 467 | 73 | 1.66 | $662,367 | $43,280 |
| 2020 | 146 | 343 | 72 | 1.75 | $389,804 | $27,358 |
| 2019 | 183 | 574 | 71 | 1.96 | $411,603 | $47,973 |
| 2018 | 151 | 527 | 71 | 1.92 | $377,485 | $41,622 |
| 2017 | 51 | 116 | 73 | 1.68 | $74,372 | $10,214 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 14 services
| Long return visit (40+ min) | 61 | $9,043 | $126 |
| Exam with injections of chemical for destruction of bladder using an endoscope | 33 | $6,503 | $118 |
| Return visit (30+ min) | 62 | $5,063 | $77 |
| New patient visit (45+ min) | 25 | $2,946 | $118 |
| New patient visit (60+ min) | 13 | $2,004 | $154 |
| Diagnostic exam of bladder and urethra using an endoscope | 24 | $1,664 | $69 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 16 | $1,309 | $82 |
| Return visit (30+ min) | 11 | $975 | $89 |
| Short return visit (20+ min) | 15 | $793 | $53 |
| Insertion of device into abdomen with pressure and urine flow rate study | 16 | $431 | $27 |
| Injection procedure for imaging of bladder during voiding | 16 | $272 | $16 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 18 | $235 | $13 |
| Review by radiologist of urinary bladder and urethra images with contrast and after passing urine | 14 | $204 | $15 |
| Electronic assessment of bladder emptying | 19 | $76 | $4 |
2022: 14 services
| Long return visit (40+ min) | 46 | $6,628 | $121 |
| Return visit (30+ min) | 56 | $5,234 | $84 |
| Exam with injections of chemical for destruction of bladder using an endoscope | 24 | $3,625 | $101 |
| Long return visit (40+ min) | 19 | $2,633 | $114 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 16 | $1,784 | $111 |
| New patient visit (45+ min) | 15 | $1,727 | $115 |
| Short return visit (20+ min) | 28 | $1,509 | $52 |
| Return visit (30+ min) | 13 | $1,270 | $85 |
| Diagnostic exam of bladder and urethra using an endoscope | 18 | $1,233 | $69 |
| Insertion of device into abdomen with pressure and urine flow rate study | 16 | $575 | $36 |
| Injection procedure for imaging of bladder during voiding | 14 | $278 | $20 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 16 | $270 | $17 |
| Review by radiologist of urinary bladder and urethra images with contrast and after passing urine | 13 | $187 | $14 |
| Electronic assessment of bladder emptying | 16 | $62 | $4 |
2021: 13 services
| Long return visit (40+ min) | 50 | $7,566 | $122 |
| Return visit (30+ min) | 47 | $4,366 | $84 |
| Exam with injections of chemical for destruction of bladder using an endoscope | 19 | $3,682 | $108 |
| New patient visit (60+ min) | 15 | $2,268 | $151 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 18 | $2,089 | $116 |
| Diagnostic exam of bladder and urethra using an endoscope | 22 | $1,719 | $72 |
| New patient visit (45+ min) | 11 | $1,286 | $117 |
| Short return visit (20+ min) | 23 | $1,030 | $45 |
| Insertion of device into abdomen with pressure and urine flow rate study | 17 | $618 | $36 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 18 | $310 | $17 |
| Injection procedure for imaging of bladder during voiding | 11 | $222 | $20 |
| Review by radiologist of urinary bladder and urethra images with contrast and after passing urine | 11 | $161 | $15 |
| Electronic assessment of bladder emptying | 15 | $63 | $4 |
2020: 6 services
| Return visit (30+ min) | 52 | $4,382 | $67 |
| Exam with injections of chemical for destruction of bladder using an endoscope | 18 | $2,607 | $97 |
| Long return visit (40+ min) | 18 | $2,139 | $107 |
| New patient visit (45+ min) | 20 | $2,056 | $103 |
| Diagnostic exam of bladder and urethra using an endoscope | 16 | $1,205 | $75 |
| Short return visit (20+ min) | 20 | $958 | $48 |
2019: 12 services
| Return visit (30+ min) | 60 | $5,127 | $69 |
| New patient visit (45+ min) | 43 | $4,940 | $115 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 31 | $3,461 | $112 |
| Exam with injections of chemical for destruction of bladder using an endoscope | 13 | $2,143 | $119 |
| Diagnostic exam of bladder and urethra using an endoscope | 26 | $1,829 | $68 |
| Long return visit (40+ min) | 19 | $1,716 | $90 |
| Insertion of device into abdomen with pressure and urine flow rate study | 30 | $1,068 | $36 |
| Injection procedure for imaging of bladder during voiding | 27 | $570 | $20 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 32 | $533 | $17 |
| Insertion of temporary bladder tube | 25 | $523 | $21 |
| Review by radiologist of urinary bladder and urethra images with contrast and after passing urine | 28 | $418 | $15 |
| Electronic assessment of bladder emptying | 35 | $163 | $5 |
2018: 14 services
| Return visit (30+ min) | 51 | $4,529 | $66 |
| New patient visit (45+ min) | 39 | $4,061 | $104 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 24 | $2,638 | $110 |
| Diagnostic exam of bladder and urethra using an endoscope | 26 | $2,052 | $71 |
| Insertion of stent in ureter using an endoscope | 12 | $1,920 | $148 |
| New patient visit (60+ min) | 13 | $1,813 | $139 |
| Long return visit (40+ min) | 16 | $1,796 | $95 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 11 | $1,014 | $35 |
| Insertion of device into abdomen with pressure and urine flow rate study | 24 | $871 | $36 |
| Injection procedure for imaging of bladder during voiding | 24 | $461 | $18 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 24 | $407 | $17 |
| Insertion of temporary bladder tube | 14 | $319 | $23 |
| Review by radiologist of urinary bladder and urethra images with contrast and after passing urine | 20 | $298 | $15 |
| Electronic assessment of bladder emptying | 29 | $251 | $6 |
2017: 3 services
| New patient visit (45+ min) | 14 | $1,617 | $116 |
| Diagnostic exam of bladder and urethra using an endoscope | 12 | $1,150 | $96 |
| New patient visit (30+ min) | 12 | $792 | $66 |
Medicaid work
$30 in 2022
Medicaid paid $30 for 13 billed services this clinician did in 2022, up to 13 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, without microscopy | 13 | $30 |
| 2022 | 13 | 1 | 13 | $30 |
Drugs they prescribed that Part D paid
$230,439
Pharmacies billed $230,439 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 794) in 2024. At or below the middle of the specialty; the typical urology clinician is at 2%.
575 generic and fewer than 11 brand-name prescriptions · $230,439 in drug cost · 85 antibiotic prescriptions to 47 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Myrbetriq | 132 | $136,588 | $1,035 |
| Gemtesa | 52 | $61,825 | $1,189 |
| Estradiol | 59 | $4,571 | $77 |
| Methenamine Hippurate | 30 | $4,181 | $139 |
| Tamsulosin | 152 | $3,691 | $24 |
See all 13 drugs
| Myrbetriq | 132 | $136,588 | $1,035 |
| Gemtesa | 52 | $61,825 | $1,189 |
| Estradiol | 59 | $4,571 | $77 |
| Methenamine Hippurate | 30 | $4,181 | $139 |
| Tamsulosin | 152 | $3,691 | $24 |
| Finasteride | 133 | $2,497 | $19 |
| Trospium Chloride | 20 | $1,538 | $77 |
| Hydroxyzine | 27 | $962 | $36 |
| Alfuzosin Hcl Er | 21 | $584 | $28 |
| Nitrofurantoin | 13 | $499 | $38 |
| Nitrofurantoin Mono-Macro | 28 | $261 | $9 |
| Sulfamethoxazole-Trimethoprim | 19 | $123 | $6 |
| Cephalexin | 11 | $24 | $2 |
Year by year
| 2024 | 794 | 218 | 0% (0) | None | $230,439 |
| 2023 | 787 | 210 | 0% (0) | None | $206,394 |
| 2022 | 722 | 180 | 0% (0) | 22% | $168,870 |
| 2021 | 559 | 138 | 0% (0) | None | $121,025 |
| 2020 | 508 | 126 | 0% (0) | None | $84,339 |
| 2019 | 468 | 122 | 0% (0) | None | $81,990 |
| 2018 | 271 | 83 | None | 28% | $45,587 |
| 2017 | 44 | 24 | None | None | $7,062 |
| 2016 | 21 | None | None | None | $767 |
| 2015 | 15 | 11 | None | 0% | $313 |
| 2014 | 53 | 30 | 28% (15) | 0% | $464 |
| 2013 | 16 | 12 | None | 0% | $157 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 16 drugs
| Myrbetriq | 131 | $138,981 | $1,061 |
| Gemtesa | 22 | $28,878 | $1,313 |
| Renacidin | 12 | $6,820 | $568 |
| Estradiol | 50 | $4,758 | $95 |
| Tamsulosin | 183 | $4,222 | $23 |
| Finasteride | 123 | $2,887 | $23 |
| Methenamine Hippurate | 14 | $2,510 | $179 |
| Trospium Chloride | 25 | $2,149 | $86 |
| Hydroxyzine | 19 | $1,236 | $65 |
| Nitrofurantoin | 15 | $743 | $50 |
| Oxybutynin Chloride Er | 15 | $640 | $43 |
| Alfuzosin Hcl Er | 14 | $509 | $36 |
| Nitrofurantoin Mono-Macro | 27 | $441 | $16 |
| Sulfamethoxazole-Trimethoprim | 25 | $118 | $5 |
| Cephalexin | 16 | $94 | $6 |
| Amoxicillin | 12 | $76 | $6 |
2022: 13 drugs
| Myrbetriq | 97 | $116,638 | $1,202 |
| Renacidin | 18 | $9,528 | $529 |
| Estradiol | 44 | $5,285 | $120 |
| Tamsulosin | 164 | $3,988 | $24 |
| Methenamine Hippurate | 13 | $2,499 | $192 |
| Finasteride | 121 | $2,333 | $19 |
| Trospium Chloride | 16 | $2,046 | $128 |
| Nitrofurantoin | 27 | $1,486 | $55 |
| Hydroxyzine | 22 | $620 | $28 |
| Nitrofurantoin Mono-Macro | 33 | $251 | $8 |
| Sulfamethoxazole-Trimethoprim | 36 | $222 | $6 |
| Amoxicillin | 15 | $156 | $10 |
| Phenazopyridine | 11 | $143 | $13 |
2021: 13 drugs
| Myrbetriq | 91 | $91,034 | $1,000 |
| Renacidin | 11 | $5,872 | $534 |
| Trospium Chloride | 18 | $3,399 | $189 |
| Tamsulosin | 146 | $3,046 | $21 |
| Methenamine Hippurate | 12 | $2,779 | $232 |
| Estradiol | 16 | $2,220 | $139 |
| Finasteride | 82 | $1,641 | $20 |
| Nitrofurantoin | 24 | $1,513 | $63 |
| Oxybutynin Chloride Er | 17 | $853 | $50 |
| Nitrofurantoin Mono-Macro | 17 | $167 | $10 |
| Sulfamethoxazole-Trimethoprim | 23 | $118 | $5 |
| Amoxicillin | 14 | $115 | $8 |
| Cephalexin | 12 | $46 | $4 |
2020: 9 drugs
| Myrbetriq | 51 | $56,907 | $1,116 |
| Trospium Chloride | 27 | $5,075 | $188 |
| Estradiol | 21 | $3,931 | $187 |
| Tamsulosin | 155 | $3,422 | $22 |
| Oxybutynin Chloride Er | 48 | $2,600 | $54 |
| Finasteride | 81 | $1,682 | $21 |
| Nitrofurantoin | 22 | $1,623 | $74 |
| Hydroxyzine | 18 | $211 | $12 |
| Nitrofurantoin Mono-Macro | 15 | $121 | $8 |
2019: 10 drugs
| Myrbetriq | 43 | $39,429 | $917 |
| Tolterodine Tartrate Er | 26 | $6,004 | $231 |
| Estradiol | 27 | $4,865 | $180 |
| Premarin | 11 | $4,837 | $440 |
| Trospium Chloride | 28 | $3,610 | $129 |
| Oxybutynin Chloride Er | 53 | $2,876 | $54 |
| Tamsulosin | 114 | $2,622 | $23 |
| Finasteride | 47 | $1,279 | $27 |
| Nitrofurantoin | 15 | $882 | $59 |
| Cephalexin | 17 | $635 | $37 |
2018: 8 drugs
| Myrbetriq | 27 | $16,575 | $614 |
| Tolterodine Tartrate Er | 24 | $6,226 | $259 |
| Premarin | 13 | $5,800 | $446 |
| Trospium Chloride | 13 | $1,251 | $96 |
| Oxybutynin Chloride Er | 26 | $1,039 | $40 |
| Tamsulosin | 47 | $875 | $19 |
| Nitrofurantoin | 15 | $560 | $37 |
| Finasteride | 23 | $549 | $24 |
2014: 2 drugs
| Tamsulosin | 11 | $166 | $15 |
| Hydrocodone-Acetaminophen | 15 | $97 | $6 |
Money from drug and device companies
$33 in 2025
| 2025 | 1 | 2 | None | $33 |
| 2024 | 1 | 1 | None | $148 |
| 2019 | 2 | 3 | None | $264 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Ambu | None | $33 | 2 payments
|
See all 2 published payments
| Ambu | Meals · 2025-01-27 | None | $18 |
| Ambu | Meals · 2025-01-23 | None | $16 |
See earlier years (2024, 2019)
2024: $148
| Bluewind Medical | Revi | $148 | 1 payment
|
2019: $264
| Allergan | Botox Cosmetic | $186 | 2 payments
|
| Astellas Pharma US | Xtandi | $78 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1285950329
- Licence
- CA A133671California A133671: Current · expires 2026-12-31
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Urology (208800000X); Federal specialty code 2088F0040X (2088F0040X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2010-04-14
- NPI last updated
- 2024-03-13
- NPI record certified
- 2024-03-13
This is when the NPI record was last certified, not a medical board exam.